## Murat Akova

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/5700333/murat-akova-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

115
papers

9,912
citations

h-index

99
g-index

133
ext. papers

7.7
ext. citations

7.7
avg, IF

L-index

#	Paper	IF	Citations
115	A retrospective observational cohort study of the clinical epidemiology of bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae in an OXA-48 endemic setting <i>International Journal of Antimicrobial Agents</i> , <b>2022</b> , 106554	14.3	1
114	The Role of Colistin in the Era of New Lactam/Lactamase Inhibitor Combinations <i>Antibiotics</i> , <b>2022</b> , 11,	4.9	3
113	Effect of Combination Antibiotic Empirical Therapy on Mortality in Neutropenic Cancer Patients with Pneumonia <i>Microorganisms</i> , <b>2022</b> , 10,	4.9	1
112	Characteristics and outcomes of carbapenemase harbouring carbapenem-resistant Klebsiella spp. bloodstream infections: a multicentre prospective cohort study in an OXA-48 endemic setting <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , <b>2022</b> , 1	5.3	2
111	Is there still a room for improvement in antimicrobial use in a setting where use of broad-spectrum antibiotics require approval of an infectious diseases physician?. <i>Infection Control and Hospital Epidemiology</i> , <b>2022</b> , 1-3	2	
110	European Society of clinical microbiology and infectious diseases (ESCMID) guidelines for the treatment of infections caused by Multidrug-resistant Gram-negative bacilli (endorsed by ESICM-European Society of intensive care Medicine) Clinical Microbiology and Infection, 2021,	9.5	27
109	Gram-Negative Infections. Hematologic Malignancies, 2021, 161-179	О	1
108	CoronaVac efficacy data from Turkey - AuthorsTreply. <i>Lancet, The</i> , <b>2021</b> , 398, 1874	40	1
107	Outcome of noncritical COVID-19 patients with early hospitalization and early antiviral treatment outside the ICU. <i>Turkish Journal of Medical Sciences</i> , <b>2021</b> , 51, 411-420	2.7	8
106	A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , <b>2021</b> , 22, 276	2.8	11
105	Pulmonary nocardiosis caused by Nocardia abscessus mimicking pulmonary thromboembolism in a patient with atypical anti-glomerular basement membrane glomerulonephritis. <i>Tuberkuloz Ve Toraks</i> , <b>2021</b> , 69, 237-241	0.8	1
104	Lung and kidney perfusion deficits diagnosed by dual-energy computed tomography in patients with COVID-19-related systemic microangiopathy. <i>European Radiology</i> , <b>2021</b> , 31, 1090-1099	8	27
103	Expect the unexpected: fungemia caused by uncommon Candida species in a Turkish University Hospital. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , <b>2021</b> , 40, 1539-1545	5.3	1
102	Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. <i>Lancet, The</i> , <b>2021</b> , 398, 213-2	2 <sup>4</sup> 2 <sup>O</sup>	220
101	Etiology and prevalence of ESBLs in adult community-onset urinary tract infections in East China: A prospective multicenter study. <i>Journal of Infection</i> , <b>2021</b> , 83, 175-181	18.9	5
100	Antimicrobial de-escalation in the critically ill patient and assessment of clinical cure: the DIANA study. <i>Intensive Care Medicine</i> , <b>2020</b> , 46, 1404-1417	14.5	18
99	Fungaemia due to rare yeasts in a tertiary care university centre within 18 years. <i>Mycoses</i> , <b>2020</b> , 63, 488	- <del>4</del> 923	6

98	The effects of blood group types on the risk of COVID-19 infection and its clinical outcome. <i>Turkish Journal of Medical Sciences</i> , <b>2020</b> , 50, 679-683	2.7	79
97	Understanding resistance in Pseudomonas. <i>Intensive Care Medicine</i> , <b>2020</b> , 46, 350-352	14.5	3
96	Antimicrobial Stewardship in Hematological Patients at the intensive care unit: a global cross-sectional survey from the Nine-i Investigators Network. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , <b>2020</b> , 39, 385-392	5.3	6
95	Factors associated with severe lung disease in an adult population with cystic fibrosis: a single-center experience. <i>Turkish Journal of Medical Sciences</i> , <b>2020</b> , 50, 945-952	2.7	
94	Impact of antibiotic resistance on outcomes of neutropenic cancer patients with bacteraemia (IRONIC study): study protocol of a retrospective multicentre international study. <i>BMJ Open</i> , <b>2019</b> , 9, e025744	3	2
93	Dual Role of in Antibiotic Resistance and Virulence in Acinetobacter baumannii. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2019</b> , 63,	5.9	11
92	Infections in the Elderly Critically-Ill Patients. Frontiers in Medicine, 2019, 6, 118	4.9	26
91	Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. <i>Lancet Infectious Diseases, The</i> , <b>2019</b> , 19, e405-e421	25.5	441
90	Extended spectrum Elactamase producing enterobacteriaceae: carbapenem sparing options. <i>Expert Review of Anti-Infective Therapy</i> , <b>2019</b> , 17, 969-981	5.5	10
89	Developing definitions for invasive fungal diseases in critically ill adult patients in intensive care units. Protocol of the FUNgal infections Definitions in ICU patients (FUNDICU) project. <i>Mycoses</i> , <b>2019</b> , 62, 310-319	5.2	36
88	Comparison of Predictors and Mortality Between Bloodstream Infections Caused by ESBL-Producing Escherichia coli and ESBL-Producing Klebsiella pneumoniae. <i>Infection Control and Hospital Epidemiology</i> , <b>2018</b> , 39, 660-667	2	29
87	Antimicrobial resistance and antibiotic stewardship programs in the ICU: insistence and persistence in the fight against resistance. A position statement from ESICM/ESCMID/WAAAR round table on multi-drug resistance. <i>Intensive Care Medicine</i> , <b>2018</b> , 44, 189-196	14.5	65
86	Neuroinvasive Listeriosis: Could Petechial Hemorrhages be a Diagnostic Clue?. <i>Neurologist</i> , <b>2018</b> , 23, 86-91	1.6	1
85	Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. <i>Journal of Infection</i> , <b>2018</b> , 76, 20-37	18.9	73
84	1411. Tecioplanin (TEI) vs. Vancomycin (VAN) in Combination with Piperacillin-Tazobactam (TZP) or Meropenem (MER) as a Cause of Acute Kidney Injury (AKI). <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, S43	4 <sup>1</sup> S435	; 78
83	Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-flactamase-producing Enterobacteriaceae. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2017</b> , 72, 906-913	5.1	36
82	Prevalence of mcr-1 in Escherichia coli and Klebsiella pneumoniae recovered from bloodstream infections in China: a multicentre longitudinal study. <i>Lancet Infectious Diseases, The</i> , <b>2017</b> , 17, 400-410	25.5	139
81	Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study.	25.5	268

80	Clinical efficacy of Elactam/Elactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum Elactamase-producing Enterobacteriaceae in haematological patients with neutropaenia: a study protocol for a retrospective observational study (BICAR). BMJ Open, 2017, 7, e013268	3	8
79	An overview on severe infections in Europe. <i>Intensive Care Medicine</i> , <b>2017</b> , 43, 686-689	14.5	5
78	Efficacy of <code>Lactam/Lactamase</code> Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,	5.9	31
77	Antimicrobial Stewardship in Hematology Patients <b>2017</b> , 205-217		
76	Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study. <i>International Journal of Antimicrobial Agents</i> , <b>2017</b> , 50, 664-672	14.3	8
75	Bacteremic and non-bacteremic pneumonia caused by Acinetobacter baumannii in ICUs of South China: A Clinical and Microbiological Study. <i>Scientific Reports</i> , <b>2017</b> , 7, 15279	4.9	8
74	Community-acquired pneumonia in adults: Highlighting missed opportunities for vaccination. <i>European Journal of Internal Medicine</i> , <b>2017</b> , 37, 13-18	3.9	14
73	High prevalence of ESBL-producing Escherichia coli and Klebsiella pneumoniae in community-onset bloodstream infections in China. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2017</b> , 72, 273-280	5.1	61
72	Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum Lactamase-Producing Enterobacteriaceae: Results From the INCREMENT Cohort. Clinical Infectious Diseases, 2017, 65, 1615-1623	11.6	33
71	Antibacterial Resistance in Patients with Hematopoietic Stem Cell Transplantation. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , <b>2017</b> , 9, e2017002	3.2	8
70	Epidemiology of carbapenem-resistant Klebsiella pneumoniae colonization: a surveillance study at a Turkish university hospital from 2009 to 2013. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2016</b> , 85, 466-70	2.9	18
69	Epidemiology of antimicrobial resistance in bloodstream infections. <i>Virulence</i> , <b>2016</b> , 7, 252-66	4.7	88
68	Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2016</b> , 71, 1672-80	5.1	33
67	Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Indensive care unit patients (DALI) cohort. <i>Journal of Antimicrobial</i>	5.1	104
66	Prospective Evaluation of Infection Episodes in Cancer Patients in a Tertiary Care Academic Center: Microbiological Features and Risk Factors for Mortality. <i>Turkish Journal of Haematology</i> , <b>2016</b> , 33, 311-3	3f <del>9</del> 9	8
65	Reducing the impact of carbapenem-resistant Enterobacteriaceae on vulnerable patient groups: what can be done?. <i>Current Opinion in Infectious Diseases</i> , <b>2016</b> , 29, 555-560	5.4	7
64	A Multinational, Preregistered Cohort Study of Lactam/Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-Lactamase-Producing Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2016</b> , 60, 4159-69	5.9	96
63	A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae. <i>Mayo Clinic Proceedings</i> , <b>2016</b> , 91, 1362-1371	6.4	66

## (2014-2015)

62	Pharmacokinetic variability and exposures of fluconazole, anidularungin, and casporungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study. <i>Critical Care</i> , <b>2015</b> , 19, 33	10.8	83
61	Task force on management and prevention of Acinetobacter baumannii infections in the ICU. <i>Intensive Care Medicine</i> , <b>2015</b> , 41, 2057-75	14.5	95
60	Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. <i>Thorax</i> , <b>2015</b> , 70, 984-9	7.3	153
59	Evaluation of a new chromogenic medium, chromID OXA-48, for recovery of carbapenemase-producing Enterobacteriaceae from patients at a university hospital in Turkey. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , <b>2015</b> , 34, 519-25	5.3	20
58	Epidemiology of candidaemia in a tertiary care university hospital: 10-year experience with 381 candidaemia episodes between 2001 and 2010. <i>Mycoses</i> , <b>2015</b> , 58, 498-505	5.2	20
57	Epidemiology and emerging resistance in bacterial bloodstream infections in patients with hematologic malignancies. <i>Infectious Diseases</i> , <b>2015</b> , 47, 686-93	3.1	34
56	The global threat of antimicrobial resistance: science for intervention. <i>New Microbes and New Infections</i> , <b>2015</b> , 6, 22-9	4.1	581
55	Discontinuation of empirical antibiotic therapy in neutropenic leukaemia patients with fever of unknown origin is ethical. <i>Clinical Microbiology and Infection</i> , <b>2015</b> , 21, e25-7	9.5	19
54	Recommendations for Risk Categorization and Prophylaxis of Invasive Fungal Diseases in Hematological Malignancies: A Critical Review of Evidence and Expert Opinion (TEO-4). <i>Turkish Journal of Haematology</i> , <b>2015</b> , 32, 100-17	0.9	4
53	Microbiological Background <b>2015</b> , 63-87		
52	Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. <i>Journal of Infection</i> , <b>2014</b> , 68, 321-31	18.9	165
51	ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. <i>Clinical Microbiology and Infection</i> , <b>2014</b> , 20 Suppl 3, 27-46	9.5	291
50	ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi. <i>Clinical Microbiology and Infection</i> , <b>2014</b> , 20 Suppl 3, 47-75	9.5	207
40	ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis		
49	2013. Clinical Microbiology and Infection, <b>2014</b> , 20 Suppl 3, 5-26	9.5	413
48		9.5	4 <sup>1</sup> 3
	2013. Clinical Microbiology and Infection, 2014, 20 Suppl 3, 5-26  Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: lessons from the DALI Study. International Journal of Antimicrobial		
48	2013. Clinical Microbiology and Infection, 2014, 20 Suppl 3, 5-26  Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: lessons from the DALI Study. International Journal of Antimicrobial Agents, 2014, 43, 423-30  ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast	14.3	29

44	Reply to Rhodes et al. Clinical Infectious Diseases, 2014, 59, 907-8	11.6	2
43	Risk factors for target non-attainment during empirical treatment with Elactam antibiotics in critically ill patients. <i>Intensive Care Medicine</i> , <b>2014</b> , 40, 1340-51	14.5	112
42	The features of infectious diseases departments and anti-infective practices in France and Turkey: a cross-sectional study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , <b>2014</b> , 33, 1591-9	5.3	2
41	Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study. <i>Critical Care</i> , <b>2014</b> , 18, R99	10.8	65
40	Multidrug-resistant bacteria in solid organ transplant recipients. <i>Clinical Microbiology and Infection</i> , <b>2014</b> , 20 Suppl 7, 49-73	9.5	101
39	Molecular characterization of NDM-1-producing Acinetobacter pittii isolated from Turkey in 2006. Journal of Antimicrobial Chemotherapy, <b>2014</b> , 69, 3437-8	5.1	17
38	A multidisciplinary team approach to the management of patients with suspected or diagnosed invasive fungal disease. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2013</b> , 68 Suppl 3, iii25-33	5.1	8
37	Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapyEORTC infectious diseases group trial XV. Journal	2.2	63
36	Management of febrile neutropenia in the era of bacterial resistance. <i>Therapeutic Advances in Infectious Disease</i> , <b>2013</b> , 1, 37-43	2.8	22
35	Laboratory-acquired brucellosis in Turkey. <i>Journal of Hospital Infection</i> , <b>2012</b> , 80, 326-30	6.9	20
34	ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). <i>Clinical Microbiology and Infection</i> , <b>2012</b> , 18 Suppl 7, 53-67	9.5	241
33	Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. <i>Clinical Microbiology and Infection</i> , <b>2012</b> , 18, 413-31	9.5	599
32	Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria. <i>Clinical Microbiology and Infection</i> , <b>2012</b> , 18, 439-48	9.5	141
31	GRACE and the development of an education and training curriculum. <i>Clinical Microbiology and Infection</i> , <b>2012</b> , 18, E308-13	9.5	4
30	Leading infectious diseases problems in Turkey. Clinical Microbiology and Infection, 2012, 18, 1056-67	9.5	19
29	ESCMID* guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases. <i>Clinical Microbiology and Infection</i> , <b>2012</b> , 18 Suppl 7, 1-8	9.5	67
28	ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. <i>Clinical Microbiology and Infection</i> , <b>2012</b> , 18 Suppl 7, 9-18	9.5	239
27	ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. <i>Clinical Microbiology and Infection</i> , <b>2012</b> , 18 Suppl 7, 19-37	9.5	774

## (2006-2012)

26	ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. <i>Clinical Microbiology and Infection</i> , <b>2012</b> , 18 Suppl 7, 38-52	9.5	206
25	ESCMID* guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS. <i>Clinical Microbiology and Infection</i> , <b>2012</b> , 18 Suppl 7, 68-77	9.5	63
24	The Place and the Efficacy of Infectious Disease Consultations in the Hospitals. <i>Infectious Diseases in Clinical Practice</i> , <b>2012</b> , 20, 131-136	0.2	4
23	A novel fungal pathogen under the spotlightAcremonium spp. associated fungaemia in an immunocompetent host. <i>Mycoses</i> , <b>2011</b> , 54, 78-80	5.2	15
22	Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clinical Microbiology and Infection, <b>2011</b> , 17, 1859-67	9.5	420
21	European expert opinion on the management of invasive candidiasis in adults. <i>Clinical Microbiology and Infection</i> , <b>2011</b> , 17 Suppl 5, 1-12	9.5	51
20	Low-level laser therapy supported teeth extractions of two patients receiving IV zolendronate. <i>Lasers in Medical Science</i> , <b>2011</b> , 26, 569-75	3.1	16
19	Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2011</b> , 66 Suppl 1, i5-14	5.1	147
18	Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control. <i>Clinical Microbiology and Infection</i> , <b>2010</b> , 16, 102-11	9.5	182
17	Bacterial infection prevention after hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , <b>2009</b> , 44, 467-70	4.4	34
16	Sulbactam-containing beta-lactamase inhibitor combinations. <i>Clinical Microbiology and Infection</i> , <b>2008</b> , 14 Suppl 1, 185-8	9.5	40
15	The spectrum of diseases causing fever of unknown origin in Turkey: a multicenter study. <i>International Journal of Infectious Diseases</i> , <b>2008</b> , 12, 71-9	10.5	51
14	Metallo-beta-lactamases as emerging resistance determinants in Gram-negative pathogens: open issues. <i>International Journal of Antimicrobial Agents</i> , <b>2007</b> , 29, 380-8	14.3	121
13	Developing and evaluating professionalism. <i>Medical Teacher</i> , <b>2006</b> , 28, 36-9	3	20
12	Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt. <i>Clinical Infectious Diseases</i> , <b>2006</b> , 43, 1031-9	11.6	2
11	Effect of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Enterobacteriaceae other than Escherichia coli. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2006</b> , 57, 344-8	5.1	82
10	Emerging problem pathogens: A review of resistance patterns over time. <i>International Journal of Infectious Diseases</i> , <b>2006</b> , 10, S3-S8	10.5	14
9	Treatment of invasive infections due to rare or emerging yeasts and moulds. <i>Expert Opinion on Pharmacotherapy</i> , <b>2006</b> , 7, 1181-90	4	6

8	Multidrug efflux inhibition in Acinetobacter baumannii: comparison between 1-(1-naphthylmethyl)-piperazine and phenyl-arginine-beta-naphthylamide. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2006</b> , 57, 970-4	5.1	125
7	Infectious complications in patients with hematological malignancies consulted by the Infectious Diseases team: a retrospective cohort study (1997-2001). <i>Supportive Care in Cancer</i> , <b>2006</b> , 14, 52-5	3.9	18
6	Predictors of short-term outcome of spontaneous bacterial peritonitis in Turkish cirrhotic patients. Journal of Gastroenterology and Hepatology (Australia), 2005, 20, 657-60	4	8
5	A European Organization for Research and Treatment of Cancer-International Antimicrobial Therapy Group Study of secondary infections in febrile, neutropenic patients with cancer. <i>Clinical Infectious Diseases</i> , <b>2005</b> , 40, 239-45	11.6	43
4	Pharmacokinetics of liposomal amphotericin B in neutropenic cancer patients. <i>International Journal of Pharmaceutics</i> , <b>2001</b> , 213, 153-61	6.5	9
3	Nosocomial bloodstream infections in a Turkish university hospital: study of Gram-negative bacilli and their sensitivity patterns. <i>International Journal of Antimicrobial Agents</i> , <b>2001</b> , 17, 477-81	14.3	6
2	Occupational risk of hepatitis B and C infections in urologists. <i>Urologia Internationalis</i> , <b>1998</b> , 61, 206-9	1.9	1
1	Comparative In Vitro Activity of Sparfloxacin against Gram-Positive Cocci. <i>Drugs</i> , <b>1993</b> , 45, 199-200	12.1	